Abstract: Mycoplasma pneumoniae (M. pneumoniae) is increasingly recognized as a major cause of acute respiratory tract infections. Today, macrolides are used in the primary treatment of M. pneumoniae infection. However, with the increasing prevalence of strains resistant to macrolides, as well as reports of toxicity and adverse side effects, it is necessary to develop an alternative therapeutic agent. A compound recipe — Qinbaiqingfei pellets (Qinbai) — have already been approved in China as the first effective traditional Chinese medicine to be used against M. pneumoniae. Herein, we characterize the mechanism by which Qinbai interacts with M. pneumoniae and lung epithelial cells. The fact that Baicalin is the key component of Qingbai leads us to believe its study is important to elucidating the mechanism of the action of Qinbai. In this study, we describe the complex impact of Baicalin on the adhesin protein P1 of M. pneumoniae and on the expression of epidermal growth factor (EGF) in BALB/c mice and A549 cells infected with M. pneumonia. We draw the conclusion that Baicalin not only cured M. pneumoniae infection by inhibiting P1 expression, but also enhanced the repair of lung epithelial cells by upregulating EGF. Finally, we demonstrate that Baicalin plays a role in Qinbai treatment.
This is an open access article distributed under the
Creative Commons Attribution License which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
Export to BibTeX
MDPI and ACS Style
Meng, Y.; Huo, J.; Lu, W.; Wang, X.; Zhang, J.; Wang, W. Modulation of P1 and EGF Expression by Baicalin. Int. J. Mol. Sci. 2013, 14, 146-157.
Meng Y, Huo J, Lu W, Wang X, Zhang J, Wang W. Modulation of P1 and EGF Expression by Baicalin. International Journal of Molecular Sciences. 2013; 14(1):146-157.
Meng, Yanli; Huo, Jinhai; Lu, Weihong; Wang, Xin; Zhang, Junwei; Wang, Weiming. 2013. "Modulation of P1 and EGF Expression by Baicalin." Int. J. Mol. Sci. 14, no. 1: 146-157.